Published in final edited form as:

J Clin Psychiatry. 2018 ; 79(1): . doi:10.4088/JCP.16m11314.

Cost-Effectiveness of Internet-Based Cognitive-Behavioral Treatment for Bulimia Nervosa: Results of a Randomized Controlled Trial

Hunna J. Watson, PhD^{a,b,c,d,*}, Nicole McLagan, BSc(Hons)^e, Stephanie C. Zerwas, PhD^a, Ross D. Crosby, PhD^{f,g}, Michele D. Levine, PhD^h, Cristin D. Runfol, PhD^{a,i}, Christine M. Peat, PhD^{a,j}, Markus Moessner, PhD^k, Benjamin Zimmer, PhD^k, Sara M. Hofmeier, MS^a, Robert M. Hamer, PhD^{a,l,†}, Marsha D. Marcus, PhD^e, Cynthia M. Bulik, PhD^{a,m,n}, and Scott J. Crow, MD^{o,p}

^aDepartment of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

^bDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

^cSchool of Paediatrics and Child Health, The University of Western Australia, Perth, Australia

^dSchool of Psychology and Speech Pathology, Curtin University, Perth, Western Australia, Australia

^eEating Disorders Program, Princess Margaret Hospital for Children, Perth, Western Australia, Australia

^fNeuropsychiatric Research Institute, Fargo, North Dakota, United States

^gDepartment of Psychiatry and Behavioral Science, University of North Dakota School of Medicine and Health Sciences, Fargo, North Dakota, United States

^hDepartment of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

ⁱDepartment of Psychiatry and Behavioral Sciences, School of Medicine, Stanford University, Stanford, California, United States

^jDepartment of Neurosurgery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

Corresponding author: Hunna J. Watson, PhD, Department of Psychiatry, The University of North Carolina at Chapel Hill, CB #7160, 101 Manning Drive, Chapel Hill, North Carolina, USA (hunna_watson@med.unc.edu). Ph: 919-966-5546.

[†]Deceased, 28th December 2015

Trial registration: ClinicalTrials.gov identifier: [NCT00877786](https://clinicaltrials.gov/ct2/show/study/NCT00877786)

Potential conflicts of interest: Dr. Bulik is a recipient of a grant from Shire Pharmaceuticals and has served on their Advisory Board. Dr. Marcus is on the Scientific Advisory Board of Weight Watchers International, Inc. Dr. Peat is recipient of a contract from RTI and Shire Pharmaceuticals and has consulted for Sunovion Pharmaceuticals and L.E.K consulting. Dr. Watson is supported by a research grant from Shire awarded to UNC-Chapel Hill. Dr. Zerwas has consulted for L.E.K consulting. Dr. Crosby is a statistical consultant for Health Outcomes Solutions. Ms McLagan, Ms Hoffmeier, and Drs Levine, Runfol, Moessner, Zimmer, Hamer, Marcus, and Crow have no conflicts of interest to declare.

^kCenter for Psychotherapy Research, University Hospital Heidelberg, Heidelberg, Baden-Württemberg, Germany

^lDepartment of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

^mDepartment of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

ⁿDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

^oDepartment of Psychiatry, University of Minnesota Medical School, Minneapolis, Minnesota, United States

^pThe Emily Program, St Paul, Minnesota, United States

Abstract

Objective—To evaluate the cost-effectiveness of Internet-based cognitive-behavioral therapy for bulimia nervosa (CBT-BN) compared to face-to-face delivery of CBT-BN.

Methods—This paper is a planned secondary analysis of data from a randomized clinical trial (RCT). Participants were 179 adults (85% female, *M* age = 28 years) meeting DSM-IV criteria randomized to group face-to-face or group Internet-based CBT-BN for 16 sessions over 20 weeks. The cost-effectiveness analysis was conducted from a third party-payor perspective, and a partial societal perspective analysis was conducted to investigate cost-utility (i.e., cost per gain in quality-adjusted life years) and patient out-of-pocket travel-related costs. Net health care costs were calculated from protocol and non-protocol health care services using third-party payor cost estimates. The primary outcome measure in the clinical trial was abstinence from binge eating and purging, and the trial start and end dates were 2008 and 2016.

Results—The average cost per abstinent patient at post-treatment was \$7,757 (95% CI = \$4,515, \$13,361) for face-to-face and \$11,870 (95% CI = \$6,486, \$22,188) for Internet-based, and at 1-year follow-up was \$16,777 (95% CI = \$10,298, \$27,042) for face-to-face and \$14,561 (95% CI = \$10,165, \$21,028) for Internet-based CBT-BN. There were no statistically significant differences between treatment arms in cost-effectiveness or cost-utility at post-treatment or 1-year follow-up. Out-of-pocket patient costs were significantly higher for face-to-face than Internet-based therapy.

Conclusions—Third-party payor cost-effectiveness of Internet-based CBT-BN is comparable with that of an accepted standard. Internet-based dissemination of CBT-BN may be a viable alternative for patients geographically distant from specialist eating disorder services who have an unmet need for treatment.

Keywords

bulimia nervosa; cognitive-behavioral therapy; cost-effectiveness; internet; psychotherapy; randomized controlled trial

There is an urgent clinical need to make effective management of bulimia nervosa (BN) more widely available. Epidemiological data suggest that 1.5% of women will develop bulimia nervosa in their lifetime.¹ The standardized mortality rate for patients with BN is

twice as high as the annual death rate from all causes.² BN is a markedly distressing, time-consuming illness with substantial social, occupational, and financial impairments.³ The impacts place the illness as a significant cause of burden of disease, particularly among young adult women.⁴

Studies on long-term course suggest that BN may persist throughout adulthood without treatment. In a community study of Finnish female twins, 45% of individuals still had the illness five years after onset, and fewer than a third of cases had been detected by health professionals.⁵ Other estimates suggest that fewer than 1 in 5 women with an eating disorder receive professional help.⁶ Evidence-based treatments have been developed and the best-supported treatment is cognitive-behavioral therapy specifically tailored for bulimia nervosa (CBT-BN).⁷ The efficacy of CBT-BN has been demonstrated in many modes of delivery including individual therapy, group therapy, Internet-based treatment, and other formats.⁷ However, the accessibility of CBT-BN is a major issue because it is generally provided only by highly trained specialized eating disorder practitioners in urban-based settings; furthermore, this treatment is not widely distributed, even in urban settings. Informing efforts to disseminate treatment is therefore a public health priority.

In addition to accessibility, cost of eating disorder treatment is a concern, in part as eating disorders are perceived to be difficult and expensive to treat. The setting of limited health care resources also makes cost of treatment an issue of interest to third party payors. Increasingly, studies that examine the clinical effectiveness of eating disorder treatment also attend to the cost-effectiveness of the evaluated interventions.⁸ One way to improve the cost-effectiveness of treatments is to make them more effective, but changes to treatment delivery that lower costs also have potential to improve cost-effectiveness.

E-health interventions for eating disorders including Internet-based treatment have recently proliferated.⁹ In studies of Internet-based CBT, efficacy has been demonstrated, and rates of binge-purge abstinence have ranged from 14 to 37% at post-treatment and from 30 to 39% at follow-up.^{10–12} E-health facilitates access among individuals with geographical and other practical constraints, or individuals reluctant to attend face-to-face psychotherapy due to stigma, shame, or social anxiety.¹³ Improving access to effective care is likely to improve health outcomes and mitigate long-term morbidity. However, no studies have examined whether Internet-based CBT-BN is a cost-effective alternative to standard face-to-face CBT-BN. Hence, this study aimed to investigate this question. The hypotheses were that Internet-based CBT-BN would be at least as cost-effective as face-to-face CBT-BN, with effectiveness measured in terms of abstinence from binge eating and purging and improvement in quality of life.

Method

Participants

Participants in the current study comprised 179 adults randomized to face-to-face CBT-BN ($n = 90$) and Internet-based CBT-BN ($n = 89$). The trial was registered on ClinicalTrials.gov (identifier: [NCT00877786](https://clinicaltrials.gov/ct2/show/study/NCT00877786)) and has been published.¹² The hypothesis in the non-inferiority

trial was that the proportion achieving abstinence in Internet-based CBT-BN would be non-inferior to face-to-face CBT-BN.

Briefly, the RCT took place at two sites, the University of North Carolina at Chapel Hill (UNC) and at Western Psychiatric Institute and Clinic of the University of Pittsburgh Medical Center (UPMC). Participants met inclusion criteria of Diagnostic and Statistical Manual Fourth Edition (DSM-IV)¹⁴ bulimia nervosa, 18 years, English-speaking, with reliable and private Internet access. Individuals were ineligible if they had a medical problem or developmental disability that would interfere with treatment, alcohol/drug dependence, severe suicidal ideation, schizophrenia, psychosis, bipolar disorder, or were pregnant. The study was conducted using an intent-to-treat approach. From the 196 in total randomized, only individuals who withdrew consent ($n = 13$), were terminated ($n = 3$; i.e., had a change in status during the study and met exclusion criteria), and had a missing baseline assessment ($n = 1$) were excluded. The study was approved by the institutional review boards at UNC and UPMC.

Procedures

Details of the design have been published previously.^{12, 15} Briefly, participants were randomized to group face-to-face or group Internet-based CBT-BN. A group modality was chosen to make intervention feasible in the study contexts. Group and individual CBT are similarly effective, although some research has found that individual CBT is associated with higher abstinence.⁷ Each treatment arm included sixteen 1.5 hour sessions delivered over 20 weeks. Patients in face-to-face CBT-BN had in person group sessions at the treatment site. Patients in Internet-based CBT-BN convened with the therapist via an online chat group accessed with an anonymous username and password; the chat room was text-based messages only.

Measures

Outcome—The primary effectiveness outcome was abstinence from binge eating/purging over the past 28 days measured with the Eating Disorder Examination (EDE)¹⁶ at post-treatment and 1-year follow-up. The abstinence proportions used were those reported in the outcome paper¹²: at post-treatment, individuals with missing data were conservatively assumed to be non-abstinent in the study, and at 1-year follow-up, in light of attrition, abstinence was estimated with multiple imputation. Cost-effectiveness was calculated as the cost of treatment per abstinent patient.

The secondary effectiveness outcome was quality-adjusted life years (QALYs), measured via the Short-Form Health State Classification (SF-6D), which is derived from the SF-36, administered at baseline, post-treatment, and 1-year follow-up. The SF-6D is a utility-based measure of health-related quality of life¹⁷ and has good validity.¹⁸ The algorithm gives a value ranging between 0 (death) and 1 (perfect health). Cost-utility was calculated as the cost per QALY gained. QALY gain refers to the increase in QALYs before and after treatment; one QALY gain means that the person has gained one year in perfect health.

Intervention—Psychotherapy visits were derived from electronic attendance records. The patient was required to present at either the face-to-face or Internet-based session (i.e., securely log in) for a visit to be counted.

Nonprotocol healthcare—Patient encounters with health services that were not part of the CBT-BN trial intervention are considered to be nonprotocol costs and include, for instance, visits to primary care professionals and prescription medications. Nonprotocol healthcare was calculated for posttreatment and 1 year follow-up, using the McKnight Follow-up of Eating Disorders (M-FED). The M-FED was administered to participants at post-treatment, 3-, 6- and 12-months after treatment. The M-FED was developed for the McKnight Foundation sponsored studies of anorexia nervosa treatment,¹⁹ bulimia nervosa treatment,^{20–23} and a four year longitudinal follow-up study of eating disorders.²³ The instrument captures a wide range of healthcare services: medical monitoring, medication management, individual therapy, group therapy, family/couples therapy, nutritional management, weight management, partial hospitalization, inpatient hospitalization, and emergency room use. The instrument was developed from the Longitudinal Interval Follow-Up Evaluation²⁴ with additional questions adapted from the Structured Clinical Interview for DSM-IV (SCID)²⁵, and specific questions developed for measuring medical and mental health utilization. In this trial, only the utilization portion was employed. The version of the M-FED used in this trial was revised based on experience using it to measure medical and mental health utilization in other trials (R01 MH 59234; R01 MH 058821; R01 DK 61912; and currently 2 R01 MH 058820).

Costs

Inflation did not need to be accounted for as all cost estimates were based on costs in 2013 (i.e., the year the trial treatment phase closed).

Intervention costs—The cost of CBT-BN in each condition was captured by assigning the billing charge for group therapy in the 2013 Current Procedural Terminology (CPT).²⁶ The total per-person cost was based on the number of sessions attended by each patient.

Nonprotocol healthcare costs—Patient consumption of healthcare that was not in the study protocol was costed. For assignment of hospital inpatient costs, Diagnosis Related Grouping (DRG) diagnoses were derived from the reasons given by individuals for hospital admissions and DRG cost figures were obtained from the Center for Medicare and Medicaid Services (CMS) website (www.cms.gov). For outpatient and emergency room utilization, procedure codes were assigned using the CPT Code Book, then costs from the CMS website for these services were calculated. For medication usage, lowest average wholesale price was obtained from the Red Book, which is a drug pricing compendium aiding pharmacy operations.²⁷ Costs for medication management visits were captured from the CPT Code Book.

Gas and travel time costs—Distance traveled to the clinic for face-to-face CBT-BN was based on self-report. Average miles per gallon (MPG) was assumed from US Chamber of Commerce-Institute for 21st Century Energy data (17 miles per gallon), and average cost of

gas per gallon was assumed from US Energy Information Administration 2013 data (\$3.50 North Carolina, \$3.56 Pennsylvania). Per-person gas cost was calculated as: (return distance / average MPG) $\times$ average cost per gallon $\times$ number of sessions attended. Travel time was obtained from self-report and hourly wage was estimated from US Census Bureau 2013 per capita annual income (\$13.17/hour North Carolina, \$14.84/hour Pennsylvania). The per-person cost of time to travel to the clinic was calculated as: travel time (return travel time included) $\times$ hourly wage $\times$ number of sessions attended.

Statistical Analysis

Analyses were performed in accordance with the intent-to-treat principle and conducted with SAS 9.4. The primary perspective for this study was a third-party payor perspective, using direct medical costs. The rationale was that direct costs have greater impact on third-party payor decisions than societal perspective costs. Additionally, there is a widespread view that eating disorder treatment is expensive, as such, cost considerations play a prominent role in third-party payor decisions about coverage of care, at least in the United States.

Data management—There were missing data at post-treatment and 1-year follow-up due to attrition. When imputing missing data, the pattern of missing data is more important than the amount missing. Missing data were assumed to be missing at random (MAR) and were imputed with the expectation maximization algorithm, which produces asymptotically unbiased estimates using full-information maximum-likelihood estimation.

Third-party payor perspective—The average cost-effectiveness ratio was calculated for each treatment arm, which is the average cost of treatment for all subjects in an arm divided by the proportion achieving abstinence in that arm. Because the sample mean for cost data was not normally distributed, the bootstrapped mean (and 95% confidence limits) is provided. Bootstrapping is a non-parametric procedure that simulates the normal distribution of the mean and addresses statistical uncertainty in the cost and effect estimates. Bootstrap resampling was done with random replacement using 10,000 simulated samples. The mean cost-effectiveness ratio gives a base case estimate of the cost per abstinent subject.

Societal perspective—The analysis is limited by a lack of inclusion of productivity losses, hence it is a partial societal perspective analysis. Two analyses were conducted. Firstly, we examined change in health-related quality of life from baseline to post-treatment and baseline to 1-year follow-up to give a base case estimate of dollars per QALY gained for each treatment arm. The QALYs were calculated by multiplying the SF-6D utility score by the time spent in that health state. The conventionally accepted threshold for a cost-effective treatment is \$50,000/QALY, although some have advocated for \$110–160,000/QALY in the United States given the greater economic output.²⁸ For the purposes of this study, values below the \$50,000 QALY threshold were considered cost-effective. Bootstrap estimates were used to generate the mean estimate and to evaluate uncertainty in cost per QALY gain estimates using 10,000 simulated samples drawn with replacement. The second analysis allowed for inclusion of the cost of patient automobile fuel and time to travel to appointments, which would differ between face-to-face and Internet-based CBT-BN.

Sensitivity analyses—For the societal perspective analysis, it is realistic to consider that patients in Internet-based treatment might be charged a software cost. It is routine to exclude software development costs from analysis. However, to be conservative, we factored in a cost of \$50 per person based on the assumption that the software would be non-commercial, and that this nominal amount would cover administrative tasks such as processing orders and updating/fixing bugs.

Results

The 179 participants were mostly female, employed, and college graduates (Table 1). The mean number of treatment sessions was 8 ($SD = 5$) in both conditions. Treatment was completed (75% of sessions) by 43% ($n = 39$) in face-to-face and 39% ($n = 35$) in Internet-based CBT-BN. Costs for patients are shown in Table 2. The average total cost for health care utilization (including protocol and non-protocol costs) was \$1,473 and \$1,470 at post-treatment and \$4,142 and \$4,131 at 1-year follow-up, for face-to-face and Internet-based CBT-BN, respectively. Recall, based on the design of the study, that the posttreatment cost involves a time frame of ~5 months and includes protocol and nonprotocol costs, and that the follow-up covers a time frame of ~12 months and includes nonprotocol costs only.

Full details of the trial and clinical outcomes have been reported.¹² Briefly, with respect to the primary outcome of abstinence, Internet-based CBT-BN was inferior to face-to-face CBT-BN at post-treatment but non-inferior at 1-year follow-up. Abstinence was attained by 21% (18/90) and 14% (12/89) at post-treatment, and 26% (18/90) and 30% (26/89) at 1 year follow-up, in face-to-face and Internet-based CBT-BN, respectively. QALY gain is shown in Table 3. Over the course of treatment, participants in each group gained on average ~1 week of full health. At the end of one year, those in face-to-face had gained 4 weeks of full health and those in Internet-based gained 5 weeks. The clinical significance of these differences are small. It is important to note that the time horizon for measuring QALY gains (1 year) is a conservative one. The QALY gains from treatment for BN likely extend beyond 1 year, as BN symptoms if untreated typically last for years, so the QALY gains from treatment likely also accumulate over years and would thus be greater than this conservative analysis suggest.”

Third-Party Payor Analysis

Average cost-effectiveness ratios indicating the cost per abstinent individual for each treatment arm are shown in Table 3. At post-treatment, the cost effectiveness ratio was \$7,757 for face-to-face and \$11,870 for Internet-based CBT-BN. At 1-year follow-up, the cost-effectiveness ratios were \$16,777 for face-to-face and \$14,561 for Internet-based. The confidence limits for each treatment arm overlapped at post-treatment and at 1-year follow-up signifying that there were no statistically significant differences in cost-effectiveness between the treatment arms at either time point. Figure 1 shows a scatterplot of bootstrapped cost and effect pairs presented on the incremental cost-effectiveness plane. The axes represent differences between the treatment arms in costs and effects: negative cost differences indicate that Internet-based CBT-BN had a lower cost-estimate than face-to-face CBT-BN; and positive effectiveness/utility differences mean that Internet-based CBT-BN is

more effective than face-to-face CBT-BN. At post-treatment, the majority of estimates lie in the north-west quadrant (indicating that Internet-based CBT-BN is more costly, less effective than face-to-face CBT-BN) and south-west quadrant (indicating that Internet-based CBT-BN is less costly, less effective), and at follow-up, the majority lie in the north-east quadrant (indicating that Internet-based CBT-BN is more costly, more effective than face-to-face CBT-BN) and south-east quadrant (indicating that Internet-based CBT-BN is less costly, more effective). The 95% confidence ellipse contains the origin in its interior at post-treatment and 1-year follow-up, so there are no statistically significant differences in cost-effectiveness between conditions.

Societal Perspective Analysis

At post-treatment, the cost-utility ratio was \$73,618/QALY for face-to-face and \$59,540/QALY for Internet-based CBT-BN, and at 1-year follow-up, \$56,801/QALY for face-to-face and \$38,715/QALY for Internet-based CBT-BN (Table 3). Figure 1 shows bootstrapped cost and utility pairs on the incremental cost-effectiveness plane. The 95% confidence ellipse contains the origin in its interior, so there are no statistically significant differences between conditions in cost-utility at posttreatment or 1-year follow-up. Regarding practical significance, according to the pre-determined threshold of \$50,000/QALY, Internet-based CBT-BN was cost-effective at 1-year follow-up. At post-treatment, neither face-to-face or Internet-based CBT-BN were cost-effective according to the practical significance threshold, neither was face-to-face treatment at follow-up.

The average distance travelled to the clinic by face-to-face patients was 17 miles ($SD = 23$) and the average trip time was 28 minutes ($SD = 23$). Out-of-pocket costs of gas and travel time to attend therapy were statistically significantly different between treatment arms. At post-treatment, the average total cost was \$178 (95% CL [\$127, \$240]) for face-to-face and nil for Internet-based participants.

Sensitivity analysis

Out-of-pocket costs were \$50 (95% CL [\$50, \$50]) for Internet-based including software versus \$178 (95% CL [\$127, \$240]) for face-to-face CBT-BN. Patients in Internet-based therapy still had significantly lower out-of-pocket costs when the software was included.

Discussion

Face-to-face and Internet-based CBT-BN had similar cost-effectiveness, measured as the cost per abstinent patient. Cost-utility, measured as the cost per gain in QALYs was also comparable across intervention arms. Patient out-of-pocket costs were significantly lower in Internet-based treatment due to the absence of travel-related costs.

Although Internet-based CBT-BN was slower to achieve its effects than face-to-face CBT-BN,¹² there were no significant differences in cost-effectiveness or cost-utility at post-treatment or 1-year follow-up. This finding has implications for the dissemination of CBT-BN. Geographically remote individuals are typically at a disadvantage as they lack the eating disorder services of their urban counterparts. Waiting lists could be reduced by being able to provide treatment at a time and location convenient to the patient (i.e., work lunch

hour). Further delivery formats that have had support include CBT delivered via telemedicine²⁹ and self-help CBT-BN with Internet support.¹⁰ Given the lack of difference in cost-effectiveness or cost-utility, third-party payors are encouraged to provide cover for empirically-supported technological solutions that increase treatment access.

Some individuals are deterred from seeking face-to-face psychotherapy because of personal barriers including embarrassment, fear of stigma, out-of-pocket costs, social anxiety, and inconvenience.³⁰ Internet-based CBT-BN may be a cost-effective way of improving access to care among individuals with personal barriers. Internet-based treatment may offer more privacy than setting foot in a clinic in the community. Participants in the Internet-based arm chose the location they accessed treatment (i.e., home) and logged in to the group chat session with an anonymous username and password that concealed their identity from other group members. Internet-based CBT-BN was associated with out-of-pocket cost savings.

There were modest gains in QALYs at post-treatment, which is not surprising given the short time-frame, and at 1-year follow-up. The QALY measure showed less sensitivity than the treatment effect measure of abstinence. Results supported the cost-utility of Internet-based CBT-BN at 1-year follow-up, but not face-to-face CBT-BN according to the conventionally used threshold, although no statistically significant differences between the two treatment arms were found. Although scores increased over time, the mean baseline, post-treatment, and 1-year follow-up SF-6D utility scores in each condition fell significantly below reported norms (~0.8 for this age group),^{31, 32} highlighting the toll of bulimia nervosa. The choice of a cost-utility threshold is a value judgment that depends on several factors; some decision-makers may conclude that these two interventions are reasonably cost-effective. The estimates fell well within the limit of US\$160,000 per year, above which few decision-makers would find acceptable. The analyses were performed from a partial societal perspective, as costs of productivity loss due to illness were not captured.

Abstinence rates seem to increase in the Internet-based arm, while decreasing in the face-to-face arm between post-treatment and 1 year, while costs are comparable in both groups. It could be that individuals in the Internet-based arm were reviewing therapy materials more frequently after treatment than those in face-to-face, as they had online access to materials.

This study has important strengths, including being the first study known to us to compare and calculate the cost-effectiveness of Internet-based CBT-BN vs. face-to-face CBT-BN. Strengths also include the rigor of therapy and clinical assessment, and wide range of nonprotocol healthcare utilization captured. Several limitations are apparent. Attrition increased over the course of the study and at 1-year follow-up the present sample may not have been large enough for missing data imputation. Simulation studies suggest that FIML imputation in general produces unbiased estimates, however large samples (i.e., 500) may be required to reveal the asymptotic distribution when attrition is higher.³³ Wider measures of societal perspective costs were unavailable. Workplace costs due to productivity losses, and further out-of-pocket expenditures by the patient and caregivers (i.e., copayments, prescription medications, binge/purge food costs, diet and purging aid costs, child care expenses, gas and travel time costs to attend nonprotocol healthcare) are examples. These likely constitute an important part of the societal costs, but are more difficult to measure. In

addition, carefully tracking some costs (i.e., cost of binge food) might impact symptom levels, confounding their accurate measurement in trials. A common argument for studying Internet-based interventions is that they are likely to cost less because of savings in clinic operating costs (i.e., administrative labor, overheads), but because these costs are not easily estimated and because the services that clinics choose to offer are heavily influenced by third-party payor decisions, it was deemed most useful to adopt a third-party payor perspective for the present study. Most participants lived within readily traveled distances to the clinic, so the travel costs underestimate the costs for patients who live further from services. Furthermore, many people would simply not access treatment from substantial distance. Even so, such individuals would remain at risk for medical complications and higher rates of other kinds of medical utilization.

This study supports Internet-based CBT-BN as a comparably cost-effective treatment to an accepted standard, face-to-face CBT-BN. Third-party payors are urged to develop and implement reimbursement schedules that increase access to effective treatment, and therapists and specialist services are encouraged to consider technologically innovative models of care.

Acknowledgments

Funding/support: This research was supported by the National Institute of Health grant (R01MH080065), the Alexander von Humboldt Stiftung (PIs: Kordy and Bulik), and a Clinical Translational Science Award (UL1TR000083). Dr. Zerwas is supported by a NIMH career development grant (K01MH100435). Drs. Peat and Runfola were supported by a NIMH post-doctoral training grant (T32MH076694). Dr. Runfola was supported by the Global Foundation for Eating Disorders (PIs: Bulik and Baucom; www.gfed.org). Benjamin Zimmer was supported by a Fellowship for Postdoctoral Researchers from the German Academic Exchange Service (DAAD). Dr. Bulik acknowledges funding from the Swedish Research Council (VR Dnr: 538-2013-8864).

The authors would like to acknowledge Hans Kordy, PhD of the University of Heidelberg (retired) and Donald Baucom, PhD of the University of North Carolina at Chapel Hill for their support and contributions to the CBT4BN project.

Role of the sponsor: The supporters had no role in the design, analysis, interpretation, or publication of this study.

References

1. Hudson JI, Hiripi E, Pope HG, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. *Biological Psychiatry*. 2007; 61(3):348–358. [PubMed: 16815322]
2. Arcelus J, Mitchell AJ, Wales J, Nielsen S. Mortality rates in patients with anorexia nervosa and other eating disorders: a meta-analysis of 36 studies. *Archives of General Psychiatry*. 2011; 68(7): 724–731. [PubMed: 21727255]
3. Deloitte Economic Access. Paying the price: The economic and social impact of eating disorders in Australia. Sydney: The Butterfly Foundation; 2012.
4. Erskine HE, Whiteford HA, Pike KM. The global burden of eating disorders. *Current Opinion in Psychiatry*. 2016; 29(6):346–353. [PubMed: 27532942]
5. Keski-Rahkonen A, Hoek H, Linna M, et al. Incidence and outcomes of bulimia nervosa: a nationwide population-based study. *Psychological Medicine*. 2009; 39(05):823–831. [PubMed: 18775085]
6. Mond JM, Hay PJ, Rodgers B, Owen C. Health service utilization for eating disorders: Findings from a community-based study. *International Journal of Eating Disorders*. 2007; 40(5):399–408. [PubMed: 17497708]

7. Shapiro JR, Berkman ND, Brownley KA, Sedway JA, Lohr KN, Bulik CM. Bulimia nervosa treatment: a systematic review of randomized controlled trials. *International Journal of Eating Disorders*. 2007; 40(4):321–336. [PubMed: 17370288]
8. Crow S. The economics of eating disorder treatment. *Current Psychiatry Reports*. 2014; 16(7):1–3.
9. Loucas CE, Fairburn CG, Whittington C, Pennant ME, Stockton S, Kendall T. E-therapy in the treatment and prevention of eating disorders: A systematic review and meta-analysis. *Behaviour Research and Therapy*. 2014; 63:122–131. [PubMed: 25461787]
10. Ljotsson B, Lundin C, Mitsell K, Carlbring P, Ramklint M, Ghaderi A. Remote treatment of bulimia nervosa and binge eating disorder: a randomized trial of Internet-assisted cognitive behavioural therapy. *Behaviour Research and Therapy*. 2007; 45(4):649–661. [PubMed: 16899213]
11. Sánchez-Ortiz V, Munro C, Stahl D, et al. A randomized controlled trial of internet-based cognitive-behavioural therapy for bulimia nervosa or related disorders in a student population. *Psychological Medicine*. 2011; 41(02):407–417. [PubMed: 20406523]
12. Zerwas SC, Watson HJ, Hofmeier SM, et al. A randomized controlled trial of online chat and face-to-face group therapy for bulimia nervosa. *Psychotherapy and Psychosomatics*. in press.
13. Hepworth N, Paxton SJ. Pathways to help-seeking in bulimia nervosa and binge eating problems: A concept mapping approach. *International Journal of Eating Disorders*. 2007; 40(6):493–504. [PubMed: 17573682]
14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4. Washington, DC: American Psychiatric Press; 1994.
15. Bulik CM, Marcus MD, Zerwas S, et al. CBT4BN versus CBTF2F: Comparison of online versus face-to-face treatment for bulimia nervosa. *Contemporary Clinical Trials*. 2012; 33(5):1056–1064. [PubMed: 22659072]
16. Fairburn, CG., Cooper, Z. The Eating Disorder Examination. In: Fairburn, CG., Wilson, GT., editors. *Binge eating: Nature, assessment, and treatment*. 12. New York: Guilford Press; 1993. p. 317–360.
17. Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. *Journal of Clinical Epidemiology*. 1998; 51(11):1115–1128. [PubMed: 9817129]
18. Petrou S, Hockley C. An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population. *Health Economics*. 2005; 14(11):1169–1189. [PubMed: 15942981]
19. Halmi KA, Agras WS, Crow S, et al. Predictors of treatment acceptance and completion in anorexia nervosa: implications for future study designs. *Archives of General Psychiatry*. 2005; 62(7):776–781. [PubMed: 15997019]
20. Agras WS, Crow SJ, Halmi KA, Mitchell JE, Wilson GT, Kraemer HC. Outcome predictors for the cognitive behavior treatment of bulimia nervosa: Data from a multisite study. *American Journal of Psychiatry*. 2000; 157(8):1302–1308. [PubMed: 10910795]
21. Mitchell JE, Agras WS, Wilson GT, Halmi K, Kraemer H, Crow S. A trial of a relapse prevention strategy in women with bulimia nervosa who respond to cognitive-behavior therapy. *International Journal of Eating Disorders*. 2004; 35(4):549–555. [PubMed: 15101070]
22. Halmi KA, Agras WS, Mitchell J, et al. Relapse predictors of patients with bulimia nervosa who achieved abstinence through cognitive behavioral therapy. *Archives of General Psychiatry*. 2002; 59(12):1105–1109. [PubMed: 12470126]
23. Crow SJ, Stewart Agras W, Halmi K, Mitchell JE, Kraemer HC. Full syndromal versus subthreshold anorexia nervosa, bulimia nervosa, and binge eating disorder: a multicenter study. *International Journal of Eating Disorders*. 2002; 32(3):309–318. [PubMed: 12210645]
24. Keller MB, Lavori PW, Friedman B, et al. The Longitudinal Interval Follow-up Evaluation: a comprehensive method for assessing outcome in prospective longitudinal studies. *Archives of General Psychiatry*. 1987; 44(6):540–548. [PubMed: 3579500]
25. First, M., Spitzer, R., Gibbon, M., Williams, J. Structured Clinical interview for DSM-IV-TR Axis I disorders, research version, patient edition (SCID-1/P). New York: Biometrics Research, New York State Psychiatric Institute; 2002.

26. Abraham, M. American Medical Association. CPT 2013: Current Procedural Terminology. Chicago: American Medical Association; 2012.
27. Physicians' Desk Reference Inc. Red book: Pharmacy's fundamental reference. Montvale, NJ: Thomson Reuters; 2013.
28. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the \$50,000-per-QALY threshold. *New England Journal of Medicine*. 2014; 371(9):796–797. [PubMed: 25162885]
29. Crow SJ, Mitchell JE, Crosby RD, Swanson SA, Wonderlich S, Lancaster K. The cost effectiveness of cognitive behavioral therapy for bulimia nervosa delivered via telemedicine versus face-to-face. *Behaviour Research and Therapy*. 2009; 47(6):451–453. [PubMed: 19356743]
30. Evans EJ, Hay PJ, Mond J, et al. Barriers to help-seeking in young women with eating disorders: a qualitative exploration in a longitudinal community survey. *Eating Disorders*. 2011; 19(3):270–285. [PubMed: 21516551]
31. Berg B. SF-6D population norms. *Health Economics*. 2012; 21(12):1508–1512. [PubMed: 22250070]
32. Fryback DG, Dunham NC, Palta M, et al. US norms for six generic health-related quality-of-life indexes from the National Health Measurement study. *Medical Care*. 2007; 45(12):1162. [PubMed: 18007166]
33. Arbuckle JL, Marcoulides GA, Schumacker RE. Full information estimation in the presence of incomplete data. *Advanced structural equation modeling: Issues and techniques*. 1996; 243:277.

Figure 1.

Bootstrapped cost and effectiveness estimates for face-to-face versus Internet-based cognitive-behavioral therapy for bulimia nervosa (CBT-BN).

The plots at the top show the mean differences in costs and effectiveness on the primary outcome measure (Eating Disorder Examination binge and purge abstinence) using 10,000 bootstrap replicates. The plots at the bottom show the mean differences in costs and utility on quality-adjusted life years (QALY) gain using 10,000 bootstrap replicates. Negative cost differences indicate that Internet-based CBT-BN had a lower cost estimate than face-to-face CBT-BN, and positive effectiveness (or utility) estimates indicate that Internet-based CBT-BN had a higher abstinence (or QALY gain) estimate than face-to-face CBT-BN. The quadrants (clockwise from top right) represent the following scenarios for Internet-based CBT-BN compared with face-to-face CBT-BN: (1) more costly and more effective, (2) less costly and more effective (ideal), (3) less costly and less effective, and (4) more costly and less effective. The ellipse indicates the 95% confidence limits.

Table 1

Study demographic and baseline characteristics.

	Face-to-face CBT-BN (<i>n</i> = 90)	Internet-based CBT-BN (<i>n</i> = 89)
Female (% , <i>n</i>)	98 (88)	98 (87)
Age, yrs (<i>M</i> ± <i>SD</i>)	27.5 (9.1)	28.5 (9.3)
White (% , <i>n</i>)	86 (77)	84 (75)
Latino (% , <i>n</i>)	4 (5)	4 (5)
Married/defacto (% , <i>n</i>)	22.2 (20)	19.1 (17)
Employed (% , <i>n</i>)	66.7 (60)	66.3 (59)
College graduate (% , <i>n</i>)	59.6 (53)	51.7 (46)
Body mass index, kg/m ² (<i>M</i> ± <i>SD</i>)	24.2 (4.7)	24.1 (5.7)
Frequency of objective binge eating (<i>M</i> ± <i>SD</i>)	14.1 (12.6)	16.4 (14.9)
Frequency of purging (<i>M</i> ± <i>SD</i>)	26.8 (20.7)	31.7 (34.2)
SF-6D (<i>M</i> ± <i>SD</i>)	0.66 (0.10)	0.66 (0.09)

Note. SF-6D = Short-Form Health State Classification.

Table 2

Summary of per-subject protocol and nonprotocol treatment costs by treatment arm.

	Face-to-face CBT-BN (<i>n</i> = 90) <i>M</i> (<i>SD</i>)		Internet-based CBT-BN (<i>n</i> = 89) <i>M</i> (<i>SD</i>)	
	Post	1 yr f/u	Post	1 yr f/u
CBT-BN	211 (144)	211 (144)	201 (142)	201 (142)
Physician visits	46 (69)	175 (245)	64 (119)	164 (223)
Medication management	74 (129)	209 (247)	84 (156)	269 (479)
Individual therapy	85 (210)	528 (838)	223 (480)	858 (1076)
Group therapy	14 (66)	32 (109)	17 (58)	44 (144)
Family/couples therapy	8 (30)	21 (78)	29 (177)	73 (317)
Nutrition counseling	33 (116)	82 (205)	15 (46)	47 (96)
Weight management	2 (15)	6 (24)	2 (6)	7 (20)
Partial hospitalization	228 (1276)	423 (2268)	90 (483)	180 (705)
Inpatient	131 (593)	293 (1219)	233 (1218)	345 (1348)
Emergency room	13 (29)	24 (46)	7 (16)	16 (29)
Prescription medication	593 (1180)	1387 (2674)	526 (868)	1477 (1931)
Total	\$1,473 (\$2,021)	\$4,142 (\$5,608)	\$1,470 (\$1,950)	\$4,131 (\$4,046)

Note. Costs are in 2013 US dollars. CBT-BN is a per-protocol cost and all other treatments are non-protocol costs. CBT-BN = cognitive behavioral therapy for bulimia nervosa.

Table 3

Cost and effectiveness of face-to-face and Internet-based cognitive-behavioral therapy for bulimia nervosa (CBT-BN)

	Face-to-face CBT-BN (<i>n</i> = 90)		Internet-based CBT-BN (<i>n</i> = 89)	
	Post	1 yr f/u	Post	1 yr f/u
Cost	\$1,473	\$4,142	\$1,470	\$4,131
Effectiveness (abstinence)	0.21	0.26	0.14	0.30
Utility gain (QALYs)	0.02	0.08	0.03	0.11
Average cost-effectiveness ratio (\$/abstinence)	\$7,757 (\$4,515, \$13,361)	\$16,777 (\$10,298, \$27,042)	\$11,870 (\$6,486, \$22,188)	\$14,561 (\$10,165, \$21,028)
Average cost-utility ratio (\$/QALY)	\$73,618 (\$42,580, \$133,815)	\$56,801 (\$34,396, \$96,906)	\$59,540 (\$36,990, \$96,641)	\$38,715 (\$26,486, \$56,739)

Note. Costs are in 2013 US dollars. QALY = quality-adjusted life years. The cost-effectiveness and cost-utility estimates are means and 95% confidence limits from bootstrapping analyses with 10,000 samples.